The companies agreed in May 2006 to co-develop and commercialize Athersys' non-embryonic stem cell platform technology for use in AMI and peripheral vascular disease

Genmab A/S, of Copenhagen, Denmark, has initiated enrollment in a Phase II study of ofatumumab (HuMax-CD20(R)) for the treatment of relapsed Diffuse Large B-Cell Lymphoma in patients ineligible for or relapsed following a stem cell transplant

Stem Cell Therapeutics Corp., of Calgary, Alberta, has received a "no objection" letter from Health Canada for the REGENESIS trial, a Phase II prospective, randomized, double-blind, placebo controlled study of NTx-265, a human chorionic gonadotropin and epoetin alfa in acute ischemic stroke patients investigating efficacy and safety endpoints

StemCells Inc., of Palo Alto, Calif., said the first patient to receive a transplant of HuCNS-SC cells (purified human neural stem cells) has completed the Phase I trial

Osiris Therapeutics Inc., of Columbia, Md., disclosed positive one-year interim results in the evaluation of Chondrogen, a preparation of adult stem cells formulated for direct injection into the knee

More than 50 percent of patients in the study had undergone stem cell transplants

Athersys Inc., of Cleveland, said the FDA cleared its investigational new drug application for MultiStem adult stem cells derived from bone marrow...The company plans to begin an open-label, Phase I, dose-escalation trial testing the drug following a bone marrow transplant conditioning regimen and hematopoietic stem cell transplantation in acute leukemia, chronic myeloid leukemia, or myelodysplasia

The 20-patient study will utilize adult stem cells derived from each patient's liposuctioned fat to augment fat transplanted to their breasts...and Gamida-Cell Ltd., both of Jerusalem, treated the first patient in the pivotal trial of StemEx, a graft of expanded stem cells and progenitor cells derived from cord blood

The myoblast therapy involves the transplantation of expanded autologous adult progenitor stem cells derived from a small biopsy of skeletal muscle from a patient's leg, the expansion of those myoblasts in the lab followed by transplantation into the patient's scarred heart tissue using 3-D eletromechanical mapping-based catheter procedure...formulation of its mesenchymal stem cells product, in Type I diabetes

The DSMB completed an interim evaluation of safety data after the two-month follow-up visits for the first 20 hematopoietic stem cell transplant recipients enrolled in the study

Aastrom Biosciences Inc. , of Ann Arbor, Mich., reported positive interim results from two research groups using autologous stem cell products manufactured with the company s Tissue Repair Cell technology platform...Those data were presented at the stem cell conference in Wurzburg, Germany

PrimeCell Therapeutics LLC, of Irvine, Calif., said results of a clinical study involving the implantation of autologous adult bone-marrow stem cells into 38 patients with spinal cord injuries revealed that some patients experienced restored function

ViaCell Inc., of Cambridge, Mass., and Children's Hospital and Research Center in Oakland, Calif., said umbilical cord blood from a relative may be an effective source of stem cells for transplantation in children affected with sickle cell disease and thalassemia, and may have advantages over bone marrow transplantation

The patient population is Philadelphia chromosome-negative adult patients in second relapse, or those patients who relapsed following two lines of anti-leukemia chemotherapy, including those who previously have undergone stem cell transplantation

Revimmune is designed to eliminate peripheral immune cells, including those responsible for autoimmunity, while sparing hematopoeitic stem cells in the bone marrow so they can regenerate healthy immune cells

Millennium Pharmaceuticals Inc., of Cambridge, Mass., has begun a randomized, multicenter Phase III trial to determine the most effective Velcade-based combination therapy with approved agents for the treatment of newly diagnosed multiple myeloma patients, ineligible for stem cell transplantation

Vical Inc., of San Diego, has begun enrollment of the 20th hematopoietic stem cell transplant recipient in the company's Phase II trial of a DNA vaccine against cytomegalovirus...The double-blind, placebo-controlled Phase II trial is designed to compare safety of the vaccine against placebo in approximately 80 matched, related donor/recipient pairs scheduled for hematopoietic stem cell transplants

Millennium Pharmaceuticals Inc., of Cambridge, Mass., reported that as an induction therapy prior to stem cell transplantation, a Velcade-based therapy in newly diagnosed multiple myeloma patients produced a high complete remission/complete response (CR) rate of 20 percent, which led to a post stem cell transplantation CR rate of 43 percent

PrimeCell Therapeutics LLC, of Sydney, Australia, said preliminary results of a 25-patient trial that involved implanting autologous bone marrow stem cells into spinal cord injury patients showed that 15 patients (60 percent) could stand, up 10 patients (40 percent) could walk on the parallels with braces, seven (28 percent) could walk without braces and four (16 percent) could walk with crutches...PrimeCell, which focuses on germ-line stem cell reprogramming, provided research support and